Lupin announced that its German subsidiary Hormosan Pharma has launched Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Germany. According to Lupin, the price of the MDI, which is a generic of Chiesi’s Foster (Fostair), will be set at just over half the reference price. Luforbec has been available in the UK since 2021.
Hormosan Pharma Managing Director Anjan Selz, Managing Director, Hormosan Pharma commented, “The launch of Luforbec 100/6 pMDI in Germany represents a significant milestone in our goal to establish Hormosan as a key player in the inhalation segment. We are committed to improving healthcare outcomes by ensuring the accessibility and affordability of reliable and comprehensive solutions for patients and healthcare professionals. This launch reinforces our dedication to making asthma and COPD management more accessible for the German population.”
Read the Lupin press release.
